Ezetimibe Alone Reduces Low-density Lipoprotein Cholesterol in HIV-infected Patients Receiving Combination Antiretroviral Therapy

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2008 Sep 11

PMID 18781882

Citations 21

Authors

David A Wohl

David Waters

Ross J Simpson Jr

Susan Richard

Amanda Schnell

Sonia Napravnik

Jessica Keys

J Joseph Eron Jr

Priscilla Hsue

Affiliations

Soon will be listed here.

Abstract

In this crossover study of ezetimibe monotherapy in 48 antiretroviral-treated patients with human immunodeficiency virus infection, the mean changes in low-density lipoprotein cholesterol were -5.3% (-11 mg/dL) and +5.5% (+4 mg/dL) with ezetimibe treatment and placebo, respectively (P = .04). Ezetimibe was safe and effective in reducing low-density lipoprotein cholesterol and is an option for patients who cannot tolerate treatment with a statin.

Citing Articles

Residual Traditional Risk in Non-Traditional Atherosclerotic Diseases.

Biscetti F, Polito G, Rando M, Nicolazzi M, Eraso L, DiMuzio P Int J Mol Sci. 2025; 26(2).

PMID: 39859250 PMC: 11765428. DOI: 10.3390/ijms26020535.

Implementation of Cholesterol-Lowering Therapy to Reduce Cardiovascular Risk in Persons Living with HIV.

Wang S, Kaur G, Schulman-Marcus J, Purga S, Mookherjee S, Miller C Cardiovasc Drugs Ther. 2020; 36(1):173-186.

PMID: 32979175 DOI: 10.1007/s10557-020-07085-8.

Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infection.

Gebhardt A, Fichtenbaum C Expert Opin Pharmacother. 2019; 20(14):1719-1729.

PMID: 31232617 PMC: 6756942. DOI: 10.1080/14656566.2019.1636033.

HIV infection and coronary heart disease: mechanisms and management.

Hsue P, Waters D Nat Rev Cardiol. 2019; 16(12):745-759.

PMID: 31182833 PMC: 8015945. DOI: 10.1038/s41569-019-0219-9.

Dysregulation of Neuronal Cholesterol Homeostasis upon Exposure to HIV-1 Tat and Cocaine Revealed by RNA-Sequencing.

Mohseni Ahooyi T, Shekarabi M, Torkzaban B, Langford T, Burdo T, Gordon J Sci Rep. 2018; 8(1):16300.

PMID: 30390000 PMC: 6215004. DOI: 10.1038/s41598-018-34539-9.

References

Iloeje U, Yuan Y, Litalien G, Mauskopf J, Holmberg S, Moorman A . Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med. 2005; 6(1):37-44. DOI: 10.1111/j.1468-1293.2005.00265.x. View

Eron Jr J, Yeni P, Gathe Jr J, Estrada V, DeJesus E, Staszewski S . The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet. 2006; 368(9534):476-82. DOI: 10.1016/S0140-6736(06)69155-1. View

Negredo E, Molto J, Puig J, Cinquegrana D, Bonjoch A, Perez-Alvarez N . Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS. 2006; 20(17):2159-64. DOI: 10.1097/01.aids.0000247573.95880.db. View

Gallant J, DeJesus E, Arribas J, Pozniak A, Gazzard B, Campo R . Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006; 354(3):251-60. DOI: 10.1056/NEJMoa051871. View

van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F . Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. 2004; 1(1):e19. PMC: 523838. DOI: 10.1371/journal.pmed.0010019. View

Gallant J, Staszewski S, Pozniak A, DeJesus E, Suleiman J, Miller M . Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004; 292(2):191-201. DOI: 10.1001/jama.292.2.191. View

. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285(19):2486-97. DOI: 10.1001/jama.285.19.2486. View

Friis-Moller N, Reiss P, Sabin C, Weber R, Monforte A, El-Sadr W . Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007; 356(17):1723-35. DOI: 10.1056/NEJMoa062744. View

Grundy S, Cleeman J, Merz C, Brewer Jr H, Clark L, Hunninghake D . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004; 44(3):720-32. DOI: 10.1016/j.jacc.2004.07.001. View

10.

Kastelein J, Akdim F, Stroes E, Zwinderman A, Bots M, Stalenhoef A . Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008; 358(14):1431-43. DOI: 10.1056/NEJMoa0800742. View

11.

Friis-Moller N, Sabin C, Weber R, Monforte A, El-Sadr W, Reiss P . Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003; 349(21):1993-2003. DOI: 10.1056/NEJMoa030218. View

12.

Coll B, Aragones G, Parra S, Alonso-Villaverde C, Masana L . Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. AIDS. 2006; 20(12):1675-7. DOI: 10.1097/01.aids.0000238418.43937.3b. View

13.

Triant V, Lee H, Hadigan C, Grinspoon S . Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007; 92(7):2506-12. PMC: 2763385. DOI: 10.1210/jc.2006-2190. View

14.

Bennett M, Johns K, Bondy G . Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Lipids Health Dis. 2007; 6:15. PMC: 1929083. DOI: 10.1186/1476-511X-6-15. View